Pacific Biosciences of California, Inc. (PACB)
Makes machines that read DNA sequences to identify genetic diseases and variations
$1.38+0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+3.4%
The outlook
PACB is trading near its 52-week lows, well below both its 50- and 200-day moving averages, though analyst consensus leans bullish with an average target about 79% above the current price. The stock sits in the lower portion of its yearly range, suggesting it remains in a downtrend despite positive analyst sentiment.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 6 analysts
Price trendBelow its 50- & 200-day averages
52-week range17% of the way from its 52-week low to high
Price targetAvg target +79% vs current price
Analyst price target
~12-month · 6 analysts$2.46average target+78.8% vs now
Now $1.38
Low $1.50High $3.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$427.1M
52-wk high
$2.73
52-wk low
$1.09
50-day avg
$1.43
200-day avg
$1.71
Trailing P/E
—